Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Citius Pharmaceuticals Inc (CTXR) vs Nutrien Ltd (NTR) Price & Performance

Citius Pharmaceuticals IncTrade
Nutrien LtdTrade

Price performance (Past 24H)

Key statistics

Citius Pharmaceuticals Inc vs Nutrien Ltd — how do they compare? Citius Pharmaceuticals Inc trades at $0.73 (market cap $20.01M), while Nutrien Ltd trades at $66.4 (market cap $32.05B). The key difference: Nutrien Ltd is far larger — about 1601.7× Citius Pharmaceuticals Inc's market cap, and Nutrien Ltd pays a 3.27% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.

CTXRNTR
Market Cap
$20.01M$32.05B
Sector
HealthBasic Materials
52-Week High
$1.82$83.94
52-Week Low
$0.48$53.64
Enterprise Value
$16.23M$43.86B
Dividend Yield
3.27%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Citius Pharmaceuticals Inc

CTXR trades at $0.7554, up 11.58% today, with a bullish technical signal from moving averages. The company reported a net loss of $37.43M for 2025, with a negative net income margin of -823.34%, but shows revenue growth from its LYMPHIR launch. Recent news highlights commercial expansion and positive clinical data presentations at ASCO 2026.

The outlook is speculative; analyst consensus is strongly bullish (83.3% Buy), but high cash burn and consistent earnings misses pose significant risks. Investment potential hinges on successful commercialization of LYMPHIR to achieve profitability.

Nutrien Ltd

Nutrien (NTR) trades at $66.43, up 0.18% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company reported mixed Q2 2026 earnings, missing EPS estimates but beating revenue expectations, driven by higher potash prices. Financials show a net income margin of 8.44% for 2025, with a P/E ratio of 13.62 indicating reasonable valuation. Recent news highlights institutional buying and dividend declarations, while cash flow trends indicate consistent operational strength amid net outflows.

Outlook remains cautiously optimistic with a consensus price target of $76.17, suggesting 14.6% upside, supported by analyst buy ratings at 60.6%. Key opportunities include structural gas arbitrage benefits and agricultural cycle recovery, but risks involve input cost pressures, volatile fertilizer demand, and earnings consistency challenges. The stock presents a value opportunity with dividend yield, though macroeconomic and sector-specific headwinds warrant monitoring.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Citius Pharmaceuticals Inc

Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.

Read more on CTXR

About Nutrien Ltd

Created in 2018 as a result of the merger between PotashCorp and Agrium, Nutrien is the world's largest fertilizer producer by capacity. Nutrien produces the three main crop nutrients--nitrogen, potash, and phosphate--although its main focus is potash, where it is the global leader in installed capacity with roughly 20% share. The company is also the largest agricultural retailer in the United States, selling fertilizers, crop chemicals, seeds, and services directly to farm customers through its brick-and-mortar stores and online platforms.

Read more on NTR